J Clin Lipidol. 2026 Jan 27:S1933-2874(26)00018-8. doi: 10.1016/j.jacl.2026.01.018. Online ahead of print.
ABSTRACT
BACKGROUND: Elevated lipoprotein(a) [Lp(a)] is an independent and causal risk factor for atherosclerotic cardiovascular disease. Increasingly, prevention societies recommend testing Lp(a) at least once for all adults.
OBJECTIVE: A quality improvement (QI) initiative aimed to increase the rates of Lp(a) ordering for patients was piloted in the general cardiology fellows' clinic at an urban academic medical center.
METHODS: QI project interventions focused on provider education and inclusion of electronic health record-based tools.
RESULTS: Over a period of 10 months, the proportion of patients with an Lp(a) order increased from 10.1% to 20.9%, and the proportion of patients with an Lp(a) result increased from 7.0% to 11.2%.
CONCLUSION: Ahead of results from ongoing clinical trials testing Lp(a)-targeted therapies, health systems can use QI methods to assess current Lp(a) ordering practices, identify patients who may benefit from future Lp(a)-targeted therapy, and plan for rapid expansion of Lp(a) testing.
PMID:41692657 | DOI:10.1016/j.jacl.2026.01.018